Health Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi By Oliver Haill 23/07
Retail & consumer Business rates cut for pubs and clubs 'a clear positive', says analyst By Oliver Haill 23/07
Industry & services Tesla's record quarter costs $71bn after Musk spending spree. Is there a silver lining? By Ian Lyall 23/07
Tech Alphabet cloud-fuelled earnings beat fails to address fundamental long-term issues By Ian Lyall 23/07
Pharma & Biotech Custom Health wins Buy rating from Stifel, then seals a pharmacy deal to match By Proactive 23/07
Retail & consumer Australia jobs surge keeps RBA rate hike firmly in play as ASX pares gains By Proactive 23/07
Health Hikma recovery story still has further to run after recent rally, says Panmure By Oliver Haill 22/07
Retail & consumer Citi analysts cut targets on Barratt Redrow with cautious eye on medium-term By Jamie Ashcroft 22/07
Tech Meta’s AI glasses position company for long-term hardware growth, Jefferies says By Emily Jarvie 22/07
Tech Alphabet set for blockbuster quarter as AI bets collide with spending fears By Angela Harmantas 22/07
What brokers say Howden deal adds to earnings outlook, says RBC ahead of results By Oliver Haill 22/07
Industry & services Tesla beat on deliveries. Can it convince investors on spending? By Angela Harmantas 22/07
